Chaber-Ciopinska A, Kiprian D, Kawecki A, Kaminski M F
Department of Gastroenterological Oncology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Department of Cancer Prevention, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Department of Gastroenterology, Hepatology and Oncology, Medical Center for Postgraduate Education, Warsaw, Poland.
Department of Head and Neck Cancer, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Best Pract Res Clin Gastroenterol. 2016 Dec;30(6):893-900. doi: 10.1016/j.bpg.2016.10.003. Epub 2016 Oct 21.
Currently curative treatment for esophageal squamous cell cancer (ESCC) is possible only in patients with early-stage, usually asymptomatic disease. In Western countries, where the incidence of ESCC is relatively low, a screening of asymptomatic, average-risk population is untenable. In order to detect early-stage ESCC or its precursor lesions it is important to identify high-risk patients and consider endoscopic surveillance in these groups. These high-risk groups include patients after curative treatment for head and neck cancer, previous endoscopic resection of ESCC, caustic injury, and patients with tylosis or achalasia. This paper discuss the evidence and proposed method of endoscopy surveillance of these high-risk patients.
目前，食管鳞状细胞癌（ESCC）的根治性治疗仅适用于早期、通常无症状的患者。在ESCC发病率相对较低的西方国家，对无症状的平均风险人群进行筛查是不可行的。为了检测早期ESCC或其前驱病变，识别高危患者并考虑对这些人群进行内镜监测非常重要。这些高危人群包括头颈部癌根治性治疗后的患者、既往ESCC内镜切除术患者、腐蚀性损伤患者以及患有掌跖角化病或贲门失弛缓症的患者。本文讨论了对这些高危患者进行内镜监测的证据和建议方法。
